title: Activity of pyocin S2 against Pseudomonas aeruginosa biofilms.
abstract: In cystic fibrosis patients, chronic lung infection with Pseudomonas aeruginosa and the associated decline in lung function are the major cause of mortality. In this report, we show that pyocin S2 displays potent activity against P. aeruginosa biofilms, thus representing a potentially improved therapeutic option. Using an invertebrate model of P. aeruginosa infection, we also show that pyocin S2 is highly active in vivo.
authors.affiliation: Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
authors.forename: Karen
authors.initials: K
authors.lastname: Smith
authors.forename: Laura
authors.initials: L
authors.lastname: Martin
authors.forename: Angela
authors.initials: A
authors.lastname: Rinaldi
authors.forename: Ranjith
authors.initials: R
authors.lastname: Rajendran
authors.forename: Gordon
authors.initials: G
authors.lastname: Ramage
authors.forename: Daniel
authors.initials: D
authors.lastname: Walker
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000494:pharmacology; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D002648:Child; D003550:Cystic Fibrosis / Q000382:microbiology; D006801:Humans; D007814:Larva / Q000187:drug effects / Q000382:microbiology / Q000502:physiology; D008168:Lung / Q000382:microbiology; D008855:Microscopy, Electron, Scanning; D009036:Moths / Q000187:drug effects* / Q000382:microbiology / Q000502:physiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology; D011709:Pyocins / Q000494:pharmacology*; D013183:Sputum / Q000382:microbiology*; D014031:Tobramycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D011709:Pyocins; D001398:Aztreonam; D014031:Tobramycin